Expression of AXIN and MACC1 in Gastric Carcinoma and Its Clinical Significance

ZHU Bo, WANG Dan-na, GONG Xiao-meng. et al

Abstract

To investigate the expression of axis inhibition protein ( AXIN) and metastasis-associated in colon cancer-1 ( MACC1 ) in gastric carcinoma and their relationship to the clinicopathologic characteristics. Methods Expressions of AXIN and MACC1 proteins were examined by immunohistochemistry containing 100 specimens of gastric tissues (gastric carcinoma group) and 60 specimens of normal gastric mucosa tissues (control group, the nearby tissues of the excised specimen of gastric cancer patients, from the tumor of the gastric cancer >5.0 cm, and confirm that there were no cancer cells). Results The positive rates of AXIN and MACC1 proteins in gastric carcinoma and the control tissues were 37. 0% vs. 83. 3% and 58. 0% vs. 6. 7%, respectively. The difference were significant between the two groups (both P<0. 05). The expressions of AXIN and MACC1 proteins were significantly related with grades of tumor, depth of invasion, lymph node metastasis, and Duke stages (P<0. 05). Spearman analysis showed that there was a negative relationship between the AXIN expression and MACC1 expression (r=— 0. 355, P<0. 05). Kaplan-Meier survival analysis and log-rank single factor analysis showed that AXIN and MACC1 protein expressions were related to the 5-year survival rate of patients (both P<0. 05). Cox regression analysis showed that the positive expression of AXIN and the negative expression MACC1 protein, and Duke stages ( Щ-IV ) were the independent prognostic factors of gastric carcinoma. Conclusion The expressions of AXIN and MACC1 proteins are related to the prognosis of gastric carcinoma patients, and are involved in the invasion and metastasis of gastric carcinoma.

 

Keywords: Gastric neoplasm, AXIN, MACCl, Immunohistochemistry, Prognosis


Full Text:

PDF


References


TORRE LA, BRAY F, SIEGEL RL. et al. Global cancer statistics, 2012. Cancer J Clin,2015,65(2) :87-108.

ZHAO P, LI YZ, LU YL. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic maker in gastric adenocarcinoma. BMC Cancer.2010,10< 1): 218-219.

ZENG L, FAGOTTO F, ZHANG T, et al. Themouse fused locus encodes Axin, an inhibitor of theWnt signaling pathway that regulates embryonic axis formation. Cell, 1997, 90( 1 ): 181-192.

CHAPMAN A, DURAND J, QUADI L, et al. Identification of genetic alterations of AXIN2 gene in adrenocortical tumors. J Clin Endocr Metab, 2011 , 96 ( 9 ); 1477-1481.

YAMAMOTO H, KISH IDA S, UOCHI T, et al. Axil, a member of the Axinfamily, interacts with both glycogen synthase kinase 3beta and betacatenin and inhibits axis formation of Xenopus embryos. Mol Cell Biol. 1998, 18(5): 2867-2875.

STEIN U, WALTHER W, ARLT F, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med, 2009 , 15 ( 1 ): 59- 67.

QIU J, HUANG P. LIU Q. et al. Identification of MACC1 as a novel prognostic maker in hepatocellular carcinoma. J Transl Med,2011,9 ; 166[2017-03-25]. https://doi.org/10. 1186/1479-5876-9-166.

HUANG Y, ZHANG H, CAI J, et al. Overexpression of MACC1 and its significance in human breast cancer progression. Cell Biosci, 2013, 3 ( 1 ): 16 [ 2017-03-25]. https;//doi. org/10. 1186/2045-3701-3-16.

MENG F. LI H, SHI H, et al. MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through akt/beta-catenin signaling pathway. PLos One, 2013,8(4): e60821 [2017-03-25]. https;//doi. org/10. 1371 /journal, pone. 0060821.

HAGEMANN C, FUCHS S, MONORANU CM, et al. Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis. Neuro Oncol, 2013, 15 (12):1696-1709.

ZHANG К, ZHANG Y, ZHU H. et al. High expression of MACC1 predicts poor prognosis in patients with osteosarcoma. Tumor Biol,2014 ,35(2); 1343-1350.

STEIN U, SMITH J, WALTHER W. et al. MACC1 controls Met; what a difference an Spl site makes. Cell Cycle, 2009,8(15):2467-2469.

ARLT F, STEIN U. Colon cancer metastasis; MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol,2009, 41(12);2356-2359.

LUO W, LIN SC. Axin; a master scaffold for multiple signaling pathways. Neurosignals,2004 ,133(3) ; 99-113.

NAKAMOTO M, MATSUYAMA A, SHI BA E. et al. Prognostic significance of WNT signaling in pancreatic ductal adenocarcinoma. Virchows Arch,2014 ,465(4) ;401-408.

HE Y, LIAN G, LIN S, et al. Mdm2 inhibits Axin-induced p53 activation independently of its E3 ligase activity. PLoS One,2013,8(6); e67529[2017-03-25]. https://doi. org/10. 1371 /journal, pone. 0067529.

MENG F, LI H. SHI H, et al. MACC1 down-regulation inhibits proliferation and tumourigenicity of nasopharyngeal carcinoma cells through Akt/j3- catenin signaling pathway. PLoS One, 2013, 8 ( 4 ); e60821 [2017-03-25]. https;//doi. org/10. 1371 /journal, pone. 0060821.

GAO J, DING F, LIU Q. et al. Knockdown of MACC1 expression suppressed hepatocellular carcinoma cell migration and invasion and inhibited expression of MMP2 and MMP9. Mol Cell Biochem,2013,376( 1/2) :21-32.

XUE H, SUN K. XIE W. et al. Etanercept attenuates short-term cigarette-smoke-exposure-induced pulmonary arterial remodelling in rats by suppressing the activation of TNF-a/NF-kB signal and the activities of MMP-2 and MMP- 9. Pulm Pharmacol Ther,2012,25(3) :208-215.

XIE C, WU J, YUN J, et аl. MACC1 as a Prognostic biomarker for early-stage and afp-normal hepatocellular carcinoma. PLoS One, 2013, 8(5): e64235 [2017-03-25]. https://doi. org/10. 1371/journal, pone. 006423.

YAMAMOTO H. MIYOSHI N, MIMORI K. et al. MACC1 expression levels as a novel prognostic marker for colorectal cancer. Oncol Lett,2014,8(5) :2305-2309.


Refbacks

  • There are currently no refbacks.